ClinicalTrials.gg
CompletedNCT00312975Updated Jun 7, 2012

Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of CP-675,206 and best supportive care in Carcinoma, Non-small-cell Lung, sponsored by AstraZeneca. Completed at 26 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-07.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies testing tremelimumab in Carcinoma, Non-Small-Cell Lung — 3 open to participants now, 8 under way, 4 of them phase 3. tremelimumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
12th of 26
90 · median 51
Started
2006
the only one that year
Phase 2
14 of 26
2 open now
Registered
1st of 26
by date
Lead sponsor
8 of 26
AstraZeneca

Among the 26 studies testing tremelimumab in Carcinoma, Non-Small-Cell Lung, this one is the 12th largest by enrollment, is the only one that started in 2006, is one of 14 in phase 2, and was the 1st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

3 of the 26 studies testing tremelimumab in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tremelimumab

tremelimumab: first FDA approval 2022 (IMJUDO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing tremelimumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this trial is to study how long patients can remain progression free when they receive CP-675,206, compared to how long patients can remain progression free when they receive best supportive care. If you choose to take part, you will be randomized to receive either CP-675,206 as maintenance therapy or best supportive care. Best supportive care means you will not receive any study drug or other treatment for your cancer. Best supportive care could include treatment with antibiotics, analgesic drugs (medicine for pain), blood transfusions or psychosocial and nutritional support, depending on your needs. You have a 50% chance of being randomized to receive CP-675,206.

03

Conditions studied

  • Carcinoma, Non-small-cell Lung
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stage IIIb (with effusion) or stage IV disease that has responded or remained stable after 6 cycles of a platinum containing regimen
  • Patients must be able to be randomized between 3 and no more than 6 weeks after the last dose of first-line therapy.

Exclusion criteria

Exclusion Criteria:

  • No other systemic therapy except platinum based treatment
  • Symptomatic or uncontrolled brain mets or uncontrolled pleural effusions.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Arm A

    Drug: CP-675,206

  • Active comparator
    Arm B

    Drug: best supportive care

Interventions

  • Given intravenously every 3 months

  • Drugbest supportive care

    As per investigator discretion. Excludes chemotherapy or other anti-cancer therapy

06

What researchers measure

Primary outcomes

  1. The length of time until there is evidence of disease progression in patients treated with CP-675,206 and in patients receiving best supportive care.

    Time frame: 3 months to 2 years from randomization

Secondary outcomes

  1. Survival

    Time frame: 2 years

  2. Levels of study drug in blood samples taken at specified time points.

    Time frame: up to 2 years

  3. Whether polymorphisms of certain genes influence safety.

    Time frame: up to 2 years

  4. Health-related quality of life outcomes.

    Time frame: up to 2 years

  5. Tumor response

    Time frame: up to 2 years

  6. Number of patients with adverse events as a measure of safety of CP-675,206 when administered to patients with NSCLC

    Time frame: up to 2 years

  7. Blood levels of any human anti-human antibody response

    Time frame: up to 2 years

  8. Immune response.

    Time frame: up to 2 years

  9. Efficacy

    Time frame: up to 2 years

07

Study locations

26 sites
  • Research Site
    Bentonville, Arkansas 72712, United States
  • Research Site
    Fayetteville, Arkansas 72703, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    Danbury, Connecticut 06810, United States
  • Research Site
    Atlanta, Georgia 30309, United States
  • Research Site
    Lexington, Kentucky 40536-0098, United States
  • Research Site
    Alexandria, Louisiana 71301, United States
  • Research Site
    New York, New York 10032, United States
  • Research Site
    Oneida, New York 13421, United States
  • Research Site
    Oswego, New York 13126, United States
  • Research Site
    Syracuse, New York 13202, United States
  • Research Site
    Syracuse, New York 13210-2306, United States
  • Research Site
    Canton, Ohio 44718, United States
  • Research Site
    Philadelphia, Pennsylvania 19111, United States
  • Research Site
    Calgary, Alberta T2N 4N2, Canada
  • Research Site
    Calgary, Alberta T2S 3C3, Canada
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
  • Research Site
    Praha 8, 180 81, Czech Republic
  • Research Site
    Tabor, 390 03, Czech Republic
  • Research Site
    Usti nad Labem, 401 13, Czech Republic
  • Research Site
    Seoul, 110-744, Korea, Republic of
  • Research Site
    Seoul, 135-710, Korea, Republic of
  • Research Site
    Seoul, 137-701, Korea, Republic of
  • Research Site
    Southampton, Hampshire SO16 6YD, United Kingdom
  • Research Site
    London, SE1 9RT, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Apr 2008 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2006
First posted
Apr 11, 2006
Start
May 2006
Primary completionActual
Apr 2008
CompletionActual
Feb 2010
Results delay requested
Apr 20, 2009
Last update
Jun 7, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00312975
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 11, 2006
Start date
May 2006
Primary completion
Apr 2008
Completion
Feb 2010
Last update
Jun 7, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tremelimumab

Start the discussion